1. New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006 
Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz, Francesco Montorsi 
European Urology Supplements 
Volume 6, Issue 4, Pages (March 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
von Hippel-Lindau (VHL)/hypoxia-inducible factor (HIF) pathway and target genes. Inactivation of the VHL gene leads to accumulation of HIF and activation of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and transforming growth factor-α (TGF-α) [6] Reprinted from Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633–43, with permission from the European Association of Urology.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Partial nephrectomy (PN) remains relatively uncommon in the United States compared with radical nephrectomy (RN) [13].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
The percentage of patients with renal tumours ≤7cm and <2cm treated with partial nephrectomy (PN) increases from 1988 to 2001 [13].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions